Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 10/2016

01-07-2016 | Adis Drug Evaluation

Sugammadex: A Review of Neuromuscular Blockade Reversal

Author: Gillian M. Keating

Published in: Drugs | Issue 10/2016

Login to get access

Abstract

Sugammadex (Bridion®) is a modified γ-cyclodextrin that reverses the effect of the steroidal nondepolarizing neuromuscular blocking agents rocuronium and vecuronium. Intravenous sugammadex resulted in rapid, predictable recovery from moderate and deep neuromuscular blockade in patients undergoing surgery who received rocuronium or vecuronium. Recovery from moderate neuromuscular blockade was significantly faster with sugammadex 2 mg/kg than with neostigmine, and recovery from deep neuromuscular blockade was significantly faster with sugammadex 4 mg/kg than with neostigmine or spontaneous recovery. In addition, recovery from neuromuscular blockade was significantly faster when sugammadex 16 mg/kg was administered 3 min after rocuronium than when patients spontaneously recovered from succinylcholine. Sugammadex also demonstrated efficacy in various special patient populations, including patients with pulmonary disease, cardiac disease, hepatic dysfunction or myasthenia gravis and morbidly obese patients. Intravenous sugammadex was generally well tolerated. In conclusion, sugammadex is an important option for the rapid reversal of rocuronium- or vecuronium-induced neuromuscular blockade.
Literature
1.
Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl. 2002;41(2):266–70.CrossRefPubMed
2.
Miller RD. Sugammadex: an opportunity to change the practice of anesthesiology? Anesth Analg. 2007;104(3):477–8.CrossRefPubMed
3.
Bartkowski RR. Incomplete reversal of pancuronium neuromuscular blockade by neostigmine, pyridostigmine, and edrophonium. Anesth Analg. 1987;66(7):594–8.CrossRefPubMed
4.
Donati F. Sugammadex: an opportunity for more thinking or more cookbook medicine? Can J Anaesth. 2007;54(9):689–95.CrossRefPubMed
5.
6.
7.
Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg. 2007;104(3):575–81.CrossRefPubMed
8.
Gijsenbergh F, Ramael S, Houwing N, et al. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology. 2005;103(4):695–703.CrossRefPubMed
9.
White PF, Tufanogullari B, Sacan O, et al. The effect of residual neuromuscular blockade on the speed of reversal with sugammadex. Anesth Analg. 2009;108(3):846–51.CrossRefPubMed
10.
Vanacker BF, Vermeyen KM, Struys MMRF, et al. Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth Analg. 2007;104(3):563–8.CrossRefPubMed
11.
Rex C, Wagner S, Spies C, et al. Reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients randomized to sevoflurane or propofol maintenance anesthesia. Anesthesiology. 2009;111(1):30–5.CrossRefPubMed
12.
Illman H, Antila H, Olkkola KT. Reversal of neuromuscular blockade by sugammadex does not affect EEG derived indices of depth of anesthesia. J Clin Monit Comput. 2010;24(5):371–6.CrossRefPubMed
13.
Fassoulaki A, Chondrogiannis K, Staikou C. Sugammadex at both high and low doses does not affect the depth of anesthesia or hemodynamics: a randomized double blind trial. J Clin Monit Comput. 2016. doi:10.​1007/​s10877-016-9844-6.PubMed
14.
Dahaba AA, Bornemann H, Hopfgartner E, et al. Effect of sugammadex or neostigmine neuromuscular block reversal on bispectral index monitoring of propofol/remifentanil anaesthesia. Br J Anaesth. 2012;108(4):602–6.CrossRefPubMed
15.
de Kam P-J, Grobara P, Prohn M, et al. Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects. Int J Clin Pharmacol Ther. 2014;52(3):227–36.CrossRefPubMed
16.
Rahe-Meyer N, Fennema H, Schulman S, et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology. 2014;121(5):969–77.CrossRefPubMed
17.
de Kam P-J, El Galta R, Kruithof AC, et al. No clinically relevant interaction between sugammadex and aspirin on platelet aggregation and coagulation parameters. Int J Clin Pharmacol Ther. 2013;51(12):976–85.CrossRefPubMed
18.
de Kam P-J, Kruithof AC, van Lierop M-J, et al. Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects. Int J Clin Pharmacol Ther. 2014;52(8):631–41.CrossRefPubMed
19.
Raft J, Guerci P, Harter V, et al. Biological evaluation of the effect of sugammadex on hemostasis and bleeding. Korean J Anesthesiol. 2015;68(1):17–21.CrossRefPubMedPubMedCentral
20.
Cammu G, Coart D, De Graeve K, et al. Reversal of rocuronium-induced neuromuscular block with sugammadex in heart failure patients: a prospective observational study. Acta Anaesthesiol Belg. 2012;63(2):69–73.PubMed
21.
de Kam P-J, van Kuijk J, Prohn M, et al. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study. Clin Drug Investig. 2010;30(9):599–611.CrossRefPubMed
22.
de Kam P-J, van Kuijk J, Smeets J, et al. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study. Int J Clin Pharmacol Ther. 2012;50(8):595–604.CrossRefPubMed
23.
de Kam P-J, Grobara P, Dennie J, et al. Effect of sugammadex on QT/QTc interval prolongation when combined with QTc-prolonging sevoflurane or propofol anaesthesia. Clin Drug Investig. 2013;33(8):545–51.CrossRefPubMed
24.
Zwiers A, van den Heuvel M, Smeets J, et al. Assessment of the potential for displacement interactions with sugammadex: a pharmacokinetic-pharmacodynamic modelling approach. Clin Drug Investig. 2011;31(2):101–11.CrossRefPubMed
25.
26.
de Kam P-J, van den Heuvel MW, Grobara P, et al. Flucloxacillin and diclofenac do not cause recurrence of neuromuscular blockade after reversal with sugammadex. Clin Drug Investig. 2012;32(3):203–12.CrossRefPubMed
27.
Pühringer FK, Gordon M, Demeyer I, et al. Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. Br J Anaesth. 2010;105(5):610–9.CrossRefPubMed
28.
Peeters P, Passier P, Smeets J, et al. Sugammadex is cleared rapidly and primarily unchanged via renal excretion. Biopharm Drug Dispos. 2011;32(3):159–67.CrossRefPubMed
29.
Staals LM, Snoeck MMJ, Driessen JJ, et al. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. Br J Anaesth. 2010;104(1):31–9.CrossRefPubMed
30.
McDonagh DL, Benedict PE, Kovac AL, et al. Efficacy, safety, and pharmacokinetics of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in elderly patients. Anesthesiology. 2011;114(2):318–29.CrossRefPubMed
31.
de Kam P-J, Hou J, Wang Z, et al. Pharmacokinetics of sugammadex 16 mg/kg in healthy Chinese volunteers. Int J Clin Pharmacol Ther. 2015;53(6):456–61.CrossRefPubMed
32.
Plaud B, Meretoja O, Hofmockel R, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology. 2009;110(2):284–94.PubMed
33.
Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology. 2006;104(4):667–74.CrossRefPubMed
34.
Suy K, Morias K, Cammu G, et al. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology. 2007;106(2):283–8.CrossRefPubMed
35.
Takeda J, Iwasaki H, Yamakage M, et al. Efficacy and safety of sugammadex (Org 25969) in reversing moderate neuromuscular block induced by rocuronium or vecuronium in Japanese patients [in Japanese]. Masui. 2014;63(10):1075–82.PubMed
36.
Tassonyi E, Pongrácz A, Nemes R, et al. Reversal of pipecuronium-induced moderate neuromuscular block with sugammadex in the presence of a sevoflurane anesthetic: a randomized trial. Anesth Analg. 2015;121(2):373–80.CrossRefPubMed
37.
Duvaldestin P, Kuizenga K, Saldien V, et al. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia. Anesth Analg. 2010;110(1):74–82.CrossRefPubMed
38.
Groudine SB, Soto R, Lien C, et al. A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg. 2007;104(3):555–62.CrossRefPubMed
39.
Takeda J, Iwasaki H, Otagiri T, et al. Efficacy and safety of sugammadex (Org 25969) in reversing deep neuromuscular block induced by rocuronium or vecuronium in Japanese patients [in Japanese]. Masui. 2014;63(10):1083–8.PubMed
40.
Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology. 2007;106(5):935–43.CrossRefPubMed
41.
Pühringer FK, Rex C, Sielenkamper AW, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology. 2008;109(2):188–97.CrossRefPubMed
42.
de Boer HD, Driessen JJ, Marcus MAE, et al. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology. 2007;107(2):239–44.CrossRefPubMed
43.
Blobner M, Eriksson LI, Scholz J, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. Eur J Anaesthesiol. 2010;27(10):874–81.CrossRefPubMed
44.
Flockton EA, Mastronardi P, Hunter JM, et al. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth. 2008;100(5):622–30.CrossRefPubMed
45.
Woo T, Kim KS, Shim YH, et al. Sugammadex versus neostigmine reversal of moderate rocuronium-induced neuromuscular blockade in Korean patients. Korean J Anesthesiol. 2014;65(6):501–7.CrossRef
46.
Wu X, Oerding H, Liu J, et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC anesthesiology. 2014;14:53.CrossRefPubMedPubMedCentral
47.
Khuenl-Brady KS, Wattwil M, Vanacker BF, et al. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesth Analg. 2010;110(1):64–73.CrossRefPubMed
48.
Illman HL, Laurila P, Antila H, et al. The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train-of-four monitoring. Anesth Analg. 2011;112(1):63–8.CrossRefPubMed
49.
Geldner G, Niskanen M, Laurila P, et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia. 2012;67(9):991–8.CrossRefPubMed
50.
Jones RK, Caldwell JE, Brull SJ, et al. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology. 2008;109(5):816–24.CrossRefPubMed
51.
Lemmens HJM, M.I. E-O, Berry J, et al. Reversal of profound vecuronium-induced neuromuscular block under sevoflurane anesthesia: sugammadex versus neostigmine. BMC Anesthesiol. 2010;10: 15.
52.
Rahe-Meyer N, Berger C, Wittmann M, et al. Recovery from prolonged deep rocuronium-induced neuromuscular blockade: a randomized comparison of sugammadex reversal with spontaneous recovery. Anaesthesist. 2015;64(7):506–12.CrossRefPubMed
53.
Soto R, Jahr JS, Pavlin J, et al. Safety and efficacy of rocuronium with sugammadex reversal versus succinylcholine in outpatient surgery: a multicenter, randomized, safety assessor-blinded trial. Am J Ther. 2015. doi:10.​1097/​MJT.​0000000000000206​.PubMed
54.
Sabo D, Jahr J, Pavlin J, et al. The increases in potassium concentrations are greater with succinylcholine than with rocuronium-sugammadex in outpatient surgery: a randomized, multicentre trial. Can J Anaesth. 2014;61(5):423–32.CrossRefPubMed
55.
Lee C, Jahr JS, Candiotti KA, et al. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology. 2009;110(5):1020–5.CrossRefPubMed
56.
Amao R, Zornow MH, Cowan RM, et al. Use of sugammadex in patients with a history of pulmonary disease. J Clin Anesth. 2012;24(4):289–97.CrossRefPubMed
57.
Dahl V, Pendeville PE, Hollmann MW, et al. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Eur J Anaesthesiol. 2009;26(10):874–84.CrossRefPubMed
58.
Fujita A, Ishibe N, Yoshihara T, et al. Rapid reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients with liver dysfunction undergoing hepatic surgery. Acta Anaesthesiol Taiwan. 2014;52(2):54–8.CrossRefPubMed
59.
Carron M, Veronese S, Foletto M, et al. Sugammadex allows fast-track bariatric surgery. Obes Surg. 2013;23(10):1558–63.CrossRefPubMed
60.
Vymazal T, Krecmerova M, Bicek V, et al. Feasibility of full and rapid neuromuscular blockade recovery with sugammadex in myasthenia gravis patients undergoing surgery: a series of 117 cases. Ther Clin Risk Manag. 2015;11:1593–6.CrossRefPubMedPubMedCentral
61.
Min KC, Bondiskey P, Schulz V, et al. Evaluation of hypersensitivity incidence following repeated single-dose sugammadex administration in healthy subjects [abstract no. 1AP15-9]. Eur J Anaesthesiol. 2015;32(Suppl 53):57.
62.
63.
Naguib M, Kopman AF, Lien CA, et al. A survey of current management of neuromuscular block in the United States and Europe. Anesth Analg. 2010;111(1):110–9.PubMed
64.
Apfelbaum JL, Silverstein JH, Chung FF, et al. Practice guidelines for postanesthetic care: an updated report by the American Society of Anesthesiologists Task Force on Postanesthetic Care. Anesthesiology. 2013;118(2):291–307.CrossRefPubMed
65.
Kotake Y, Ochiai R, Suzuki T, et al. Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block. Anesth Analg. 2013;117(2):345–51.CrossRefPubMed
66.
Sorensen MK, Bretlau C, Gatke MR, et al. Rapid sequence induction and intubation with rocuronium-sugammadex compared with succinylcholine: a randomized trial. Br J Anaesth. 2012;108(4):682–9.CrossRefPubMed
67.
Williamson RM, Mallaiah S, Barclay P. Rocuronium and sugammadex for rapid sequence induction of obstetric general anaesthesia. Acta Anaesthesiol Scand. 2011;55(6):694–9.CrossRefPubMed
68.
Stourac P, Adamus M, Seidlova D, et al. Low-dose or high-dose rocuronium reversed with neostigmine or sugammadex for cesarean delivery anesthesia: a randomized controlled noninferiority trial of time to tracheal intubation and extubation. Anesth Analg. 2016;122(5):1536–45.CrossRefPubMed
69.
Lenz A, Hill G, White PF. Emergency use of sugammadex after failure of standard reversal drugs. Anesth Analg. 2007;104(3):585–6.CrossRefPubMed
70.
de Menezes CC, Peceguini LA, Silva ED, et al. Use of sugammadex after neostigmine incomplete reversal of rocuronium-induced neuromuscular blockade. Rev Bras Anestesiol. 2012;62(4):543–7.CrossRefPubMed
71.
Pongracz A, Szatmari S, Nemes R, et al. Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train-of-four stimulation. Anesthesiology. 2013;119(1):36–42.CrossRefPubMed
72.
Kaufhold N, Schaller SJ, Stauble CG, et al. Sugammadex and neostigmine dose-finding study for reversal of residual neuromuscular block at a train-of-four ratio of 0.2 (SUNDRO20). Br J Anaesth. 2016;116:233–40.CrossRefPubMed
73.
Schaller SJ, Fink H, Ulm K, et al. Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block. Anesthesiology. 2010;113(5):1054–60.CrossRefPubMed
74.
Cammu G, van Vlem B, van den Heuvel M, et al. Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment. Br J Anaesth. 2012;109(3):382–90.CrossRefPubMed
75.
Staals LM, Snoeck MM, Driessen JJ, et al. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Br J Anaesth. 2008;101(4):492–7.CrossRefPubMed
76.
Iwasaki H, Sasakawa T, Takahoko K, et al. A case series of re-establishment of neuromuscular block with rocuronium after sugammadex reversal. J Anesth. 2016;30(3):534–7.CrossRefPubMed
Metadata
Title
Sugammadex: A Review of Neuromuscular Blockade Reversal
Author
Gillian M. Keating
Publication date
01-07-2016
Publisher
Springer International Publishing
Published in
Drugs / Issue 10/2016
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-016-0604-1

Other articles of this Issue 10/2016

Drugs 10/2016 Go to the issue

Leading Article

Long-Acting Muscarinic Antagonists for Difficult-to-Treat Asthma: Emerging Evidence and Future Directions

Current Opinion

Pain Relief for Acute Urolithiasis: The Case for Non-Steroidal Anti-Inflammatory Drugs

Letter to the Editor

Reply—Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion

Adis Drug Evaluation

Secukinumab: A Review in Ankylosing Spondylitis

Letter to the Editor

Comment on ‘What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain: Expert Opinion’

Review Article

Fimasartan: A New Angiotensin Receptor Blocker